Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AbbVie Inc presents results from global study of patient Attitudes and Adherence Across six chronic inflammatory diseases


Wednesday, 11 Jun 2014 02:00am EDT 

AbbVie Inc:Announces results from its multi country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs).Says adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy.Furthermore, patients who were "accepting" toward their medication were more often adherent, compared to patients who were "ambivalent" toward their medication, as estimated from their responses to validated questionnaires.Results were presented at the European League Against Rheumatism (EULAR) 2014 Congress in Paris.Results showed adherence to treatment, as determined by MMAS-4 scores, was generally higher in patients treated with TNF inhibitors with or without conventional therapy compared to patients treated with conventional therapy.Across all treatment types, a higher percentage of "accepting" patients were adherent to treatment compared to "ambivalent" patients based on MMAS-4 analysis and combined BMQ scores. 

Company Quote

68.22
0.01 +0.01%
6 Jul 2015